Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia
Phase 3
Completed
- Conditions
- Preeclampsia
- Interventions
- Other: Normal Saline 0.9%Biological: Recombinant human antithrombin (ATryn)
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- rEVO Biologics
- Target Recruit Count
- 120
- Registration Number
- NCT02059135
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Texas Houston School of Medicine, Houston, Texas, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors
Phase 3
Completed
- Conditions
- Hemophilia A With InhibitorsHemophilia B With Inhibitors
- Interventions
- Biological: Coagulation Factor VIIa (Recombinant)
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- rEVO Biologics
- Target Recruit Count
- 27
- Registration Number
- NCT02020369
- Locations
- 🇧🇾
Republican Research Center for Radiation Medicine and Human Ecology, Gomel, Belarus
🇵🇱Institute of Hematology and Transfusion Medicine, Warsaw, Poland
🇬🇧Basingstoke and North Hampshire Hospital, Hemophilia, Hemostasis and Thrombosis Center, Basingstoke, United Kingdom
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
Phase 1
Completed
- Conditions
- Hemophilia
- Interventions
- Biological: rhFVIIa
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- rEVO Biologics
- Target Recruit Count
- 15
- Registration Number
- NCT01708564
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
🇺🇸UC Davis Health System Internal Medicine: Hematology & Oncology, Sacramento, California, United States
🇺🇸RUSH Hemophilia & Thrombophilia Center, Chicago, Illinois, United States
Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery
Phase 3
Completed
- Conditions
- Antithrombin III Deficiency
- Interventions
- Biological: Recombinant human antithrombin (rhAT)
- First Posted Date
- 2005-05-11
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- rEVO Biologics
- Target Recruit Count
- 18
- Registration Number
- NCT00110513
Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.
Phase 3
Completed
- Conditions
- Antithrombin Deficiency, Congenital
- Interventions
- Biological: Recombinant Human Antithrombin (rhAT)
- First Posted Date
- 2003-03-18
- Last Posted Date
- 2012-10-16
- Lead Sponsor
- rEVO Biologics
- Target Recruit Count
- 14
- Registration Number
- NCT00056550
© Copyright 2025. All Rights Reserved by MedPath